Global Human Tuberculosis Vaccine Market Growth 2025-2031
The global Human Tuberculosis Vaccine market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Human Tuberculosis Vaccine Industry Forecast” looks at past sales and reviews total world Human Tuberculosis Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Human Tuberculosis Vaccine sales for 2025 through 2031. With Human Tuberculosis Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Tuberculosis Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Human Tuberculosis Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Tuberculosis Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Human Tuberculosis Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Tuberculosis Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Tuberculosis Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Tuberculosis Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Human Tuberculosis Vaccine market?
What factors are driving Human Tuberculosis Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Human Tuberculosis Vaccine market opportunities vary by end market size?
How does Human Tuberculosis Vaccine break out by Type, by Application?
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Human Tuberculosis Vaccine Industry Forecast” looks at past sales and reviews total world Human Tuberculosis Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Human Tuberculosis Vaccine sales for 2025 through 2031. With Human Tuberculosis Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Tuberculosis Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Human Tuberculosis Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Tuberculosis Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Human Tuberculosis Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Tuberculosis Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Tuberculosis Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Tuberculosis Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Intradermal
- Percutaneous
- Pediatrics
- Adults
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- GlaxoSmithKline
- Merck
- Serum Institute of India
- Valneva
- Archivel Farma
- BIOFABRI (Zendal)
- Japan BCG Laboratory
- GreenSignal Bio Pharma
- AJ Vaccines
- Taj Pharma India
- Biomed Lublin
What is the 10-year outlook for the global Human Tuberculosis Vaccine market?
What factors are driving Human Tuberculosis Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Human Tuberculosis Vaccine market opportunities vary by end market size?
How does Human Tuberculosis Vaccine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Human Tuberculosis Vaccine Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Human Tuberculosis Vaccine by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Human Tuberculosis Vaccine by Country/Region, 2020, 2024 & 2031
2.2 Human Tuberculosis Vaccine Segment by Type
2.2.1 Intradermal
2.2.2 Percutaneous
2.3 Human Tuberculosis Vaccine Sales by Type
2.3.1 Global Human Tuberculosis Vaccine Sales Market Share by Type (2020-2025)
2.3.2 Global Human Tuberculosis Vaccine Revenue and Market Share by Type (2020-2025)
2.3.3 Global Human Tuberculosis Vaccine Sale Price by Type (2020-2025)
2.4 Human Tuberculosis Vaccine Segment by Application
2.4.1 Pediatrics
2.4.2 Adults
2.5 Human Tuberculosis Vaccine Sales by Application
2.5.1 Global Human Tuberculosis Vaccine Sale Market Share by Application (2020-2025)
2.5.2 Global Human Tuberculosis Vaccine Revenue and Market Share by Application (2020-2025)
2.5.3 Global Human Tuberculosis Vaccine Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Human Tuberculosis Vaccine Breakdown Data by Company
3.1.1 Global Human Tuberculosis Vaccine Annual Sales by Company (2020-2025)
3.1.2 Global Human Tuberculosis Vaccine Sales Market Share by Company (2020-2025)
3.2 Global Human Tuberculosis Vaccine Annual Revenue by Company (2020-2025)
3.2.1 Global Human Tuberculosis Vaccine Revenue by Company (2020-2025)
3.2.2 Global Human Tuberculosis Vaccine Revenue Market Share by Company (2020-2025)
3.3 Global Human Tuberculosis Vaccine Sale Price by Company
3.4 Key Manufacturers Human Tuberculosis Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Human Tuberculosis Vaccine Product Location Distribution
3.4.2 Players Human Tuberculosis Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR HUMAN TUBERCULOSIS VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Human Tuberculosis Vaccine Market Size by Geographic Region (2020-2025)
4.1.1 Global Human Tuberculosis Vaccine Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Human Tuberculosis Vaccine Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Human Tuberculosis Vaccine Market Size by Country/Region (2020-2025)
4.2.1 Global Human Tuberculosis Vaccine Annual Sales by Country/Region (2020-2025)
4.2.2 Global Human Tuberculosis Vaccine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Human Tuberculosis Vaccine Sales Growth
4.4 APAC Human Tuberculosis Vaccine Sales Growth
4.5 Europe Human Tuberculosis Vaccine Sales Growth
4.6 Middle East & Africa Human Tuberculosis Vaccine Sales Growth
5 AMERICAS
5.1 Americas Human Tuberculosis Vaccine Sales by Country
5.1.1 Americas Human Tuberculosis Vaccine Sales by Country (2020-2025)
5.1.2 Americas Human Tuberculosis Vaccine Revenue by Country (2020-2025)
5.2 Americas Human Tuberculosis Vaccine Sales by Type (2020-2025)
5.3 Americas Human Tuberculosis Vaccine Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Tuberculosis Vaccine Sales by Region
6.1.1 APAC Human Tuberculosis Vaccine Sales by Region (2020-2025)
6.1.2 APAC Human Tuberculosis Vaccine Revenue by Region (2020-2025)
6.2 APAC Human Tuberculosis Vaccine Sales by Type (2020-2025)
6.3 APAC Human Tuberculosis Vaccine Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Human Tuberculosis Vaccine by Country
7.1.1 Europe Human Tuberculosis Vaccine Sales by Country (2020-2025)
7.1.2 Europe Human Tuberculosis Vaccine Revenue by Country (2020-2025)
7.2 Europe Human Tuberculosis Vaccine Sales by Type (2020-2025)
7.3 Europe Human Tuberculosis Vaccine Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Human Tuberculosis Vaccine by Country
8.1.1 Middle East & Africa Human Tuberculosis Vaccine Sales by Country (2020-2025)
8.1.2 Middle East & Africa Human Tuberculosis Vaccine Revenue by Country (2020-2025)
8.2 Middle East & Africa Human Tuberculosis Vaccine Sales by Type (2020-2025)
8.3 Middle East & Africa Human Tuberculosis Vaccine Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Human Tuberculosis Vaccine
10.3 Manufacturing Process Analysis of Human Tuberculosis Vaccine
10.4 Industry Chain Structure of Human Tuberculosis Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Human Tuberculosis Vaccine Distributors
11.3 Human Tuberculosis Vaccine Customer
12 WORLD FORECAST REVIEW FOR HUMAN TUBERCULOSIS VACCINE BY GEOGRAPHIC REGION
12.1 Global Human Tuberculosis Vaccine Market Size Forecast by Region
12.1.1 Global Human Tuberculosis Vaccine Forecast by Region (2026-2031)
12.1.2 Global Human Tuberculosis Vaccine Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Human Tuberculosis Vaccine Forecast by Type (2026-2031)
12.7 Global Human Tuberculosis Vaccine Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 GlaxoSmithKline
13.1.1 GlaxoSmithKline Company Information
13.1.2 GlaxoSmithKline Human Tuberculosis Vaccine Product Portfolios and Specifications
13.1.3 GlaxoSmithKline Human Tuberculosis Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 GlaxoSmithKline Main Business Overview
13.1.5 GlaxoSmithKline Latest Developments
13.2 Merck
13.2.1 Merck Company Information
13.2.2 Merck Human Tuberculosis Vaccine Product Portfolios and Specifications
13.2.3 Merck Human Tuberculosis Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Merck Main Business Overview
13.2.5 Merck Latest Developments
13.3 Serum Institute of India
13.3.1 Serum Institute of India Company Information
13.3.2 Serum Institute of India Human Tuberculosis Vaccine Product Portfolios and Specifications
13.3.3 Serum Institute of India Human Tuberculosis Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Serum Institute of India Main Business Overview
13.3.5 Serum Institute of India Latest Developments
13.4 Valneva
13.4.1 Valneva Company Information
13.4.2 Valneva Human Tuberculosis Vaccine Product Portfolios and Specifications
13.4.3 Valneva Human Tuberculosis Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Valneva Main Business Overview
13.4.5 Valneva Latest Developments
13.5 Archivel Farma
13.5.1 Archivel Farma Company Information
13.5.2 Archivel Farma Human Tuberculosis Vaccine Product Portfolios and Specifications
13.5.3 Archivel Farma Human Tuberculosis Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Archivel Farma Main Business Overview
13.5.5 Archivel Farma Latest Developments
13.6 BIOFABRI (Zendal)
13.6.1 BIOFABRI (Zendal) Company Information
13.6.2 BIOFABRI (Zendal) Human Tuberculosis Vaccine Product Portfolios and Specifications
13.6.3 BIOFABRI (Zendal) Human Tuberculosis Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 BIOFABRI (Zendal) Main Business Overview
13.6.5 BIOFABRI (Zendal) Latest Developments
13.7 Japan BCG Laboratory
13.7.1 Japan BCG Laboratory Company Information
13.7.2 Japan BCG Laboratory Human Tuberculosis Vaccine Product Portfolios and Specifications
13.7.3 Japan BCG Laboratory Human Tuberculosis Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Japan BCG Laboratory Main Business Overview
13.7.5 Japan BCG Laboratory Latest Developments
13.8 GreenSignal Bio Pharma
13.8.1 GreenSignal Bio Pharma Company Information
13.8.2 GreenSignal Bio Pharma Human Tuberculosis Vaccine Product Portfolios and Specifications
13.8.3 GreenSignal Bio Pharma Human Tuberculosis Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 GreenSignal Bio Pharma Main Business Overview
13.8.5 GreenSignal Bio Pharma Latest Developments
13.9 AJ Vaccines
13.9.1 AJ Vaccines Company Information
13.9.2 AJ Vaccines Human Tuberculosis Vaccine Product Portfolios and Specifications
13.9.3 AJ Vaccines Human Tuberculosis Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 AJ Vaccines Main Business Overview
13.9.5 AJ Vaccines Latest Developments
13.10 Taj Pharma India
13.10.1 Taj Pharma India Company Information
13.10.2 Taj Pharma India Human Tuberculosis Vaccine Product Portfolios and Specifications
13.10.3 Taj Pharma India Human Tuberculosis Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Taj Pharma India Main Business Overview
13.10.5 Taj Pharma India Latest Developments
13.11 Biomed Lublin
13.11.1 Biomed Lublin Company Information
13.11.2 Biomed Lublin Human Tuberculosis Vaccine Product Portfolios and Specifications
13.11.3 Biomed Lublin Human Tuberculosis Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Biomed Lublin Main Business Overview
13.11.5 Biomed Lublin Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. HumanTuberculosis Vaccine Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. HumanTuberculosis Vaccine Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Intradermal
Table 4. Major Players of Percutaneous
Table 5. Global HumanTuberculosis Vaccine Sales byType (2020-2025) & (K Units)
Table 6. Global HumanTuberculosis Vaccine Sales Market Share byType (2020-2025)
Table 7. Global HumanTuberculosis Vaccine Revenue byType (2020-2025) & ($ million)
Table 8. Global HumanTuberculosis Vaccine Revenue Market Share byType (2020-2025)
Table 9. Global HumanTuberculosis Vaccine Sale Price byType (2020-2025) & (US$/Unit)
Table 10. Global HumanTuberculosis Vaccine Sale by Application (2020-2025) & (K Units)
Table 11. Global HumanTuberculosis Vaccine Sale Market Share by Application (2020-2025)
Table 12. Global HumanTuberculosis Vaccine Revenue by Application (2020-2025) & ($ million)
Table 13. Global HumanTuberculosis Vaccine Revenue Market Share by Application (2020-2025)
Table 14. Global HumanTuberculosis Vaccine Sale Price by Application (2020-2025) & (US$/Unit)
Table 15. Global HumanTuberculosis Vaccine Sales by Company (2020-2025) & (K Units)
Table 16. Global HumanTuberculosis Vaccine Sales Market Share by Company (2020-2025)
Table 17. Global HumanTuberculosis Vaccine Revenue by Company (2020-2025) & ($ millions)
Table 18. Global HumanTuberculosis Vaccine Revenue Market Share by Company (2020-2025)
Table 19. Global HumanTuberculosis Vaccine Sale Price by Company (2020-2025) & (US$/Unit)
Table 20. Key Manufacturers HumanTuberculosis Vaccine Producing Area Distribution and Sales Area
Table 21. Players HumanTuberculosis Vaccine Products Offered
Table 22. HumanTuberculosis Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global HumanTuberculosis Vaccine Sales by Geographic Region (2020-2025) & (K Units)
Table 26. Global HumanTuberculosis Vaccine Sales Market Share Geographic Region (2020-2025)
Table 27. Global HumanTuberculosis Vaccine Revenue by Geographic Region (2020-2025) & ($ millions)
Table 28. Global HumanTuberculosis Vaccine Revenue Market Share by Geographic Region (2020-2025)
Table 29. Global HumanTuberculosis Vaccine Sales by Country/Region (2020-2025) & (K Units)
Table 30. Global HumanTuberculosis Vaccine Sales Market Share by Country/Region (2020-2025)
Table 31. Global HumanTuberculosis Vaccine Revenue by Country/Region (2020-2025) & ($ millions)
Table 32. Global HumanTuberculosis Vaccine Revenue Market Share by Country/Region (2020-2025)
Table 33. Americas HumanTuberculosis Vaccine Sales by Country (2020-2025) & (K Units)
Table 34. Americas HumanTuberculosis Vaccine Sales Market Share by Country (2020-2025)
Table 35. Americas HumanTuberculosis Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 36. Americas HumanTuberculosis Vaccine Sales byType (2020-2025) & (K Units)
Table 37. Americas HumanTuberculosis Vaccine Sales by Application (2020-2025) & (K Units)
Table 38. APAC HumanTuberculosis Vaccine Sales by Region (2020-2025) & (K Units)
Table 39. APAC HumanTuberculosis Vaccine Sales Market Share by Region (2020-2025)
Table 40. APAC HumanTuberculosis Vaccine Revenue by Region (2020-2025) & ($ millions)
Table 41. APAC HumanTuberculosis Vaccine Sales byType (2020-2025) & (K Units)
Table 42. APAC HumanTuberculosis Vaccine Sales by Application (2020-2025) & (K Units)
Table 43. Europe HumanTuberculosis Vaccine Sales by Country (2020-2025) & (K Units)
Table 44. Europe HumanTuberculosis Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 45. Europe HumanTuberculosis Vaccine Sales byType (2020-2025) & (K Units)
Table 46. Europe HumanTuberculosis Vaccine Sales by Application (2020-2025) & (K Units)
Table 47. Middle East & Africa HumanTuberculosis Vaccine Sales by Country (2020-2025) & (K Units)
Table 48. Middle East & Africa HumanTuberculosis Vaccine Revenue Market Share by Country (2020-2025)
Table 49. Middle East & Africa HumanTuberculosis Vaccine Sales byType (2020-2025) & (K Units)
Table 50. Middle East & Africa HumanTuberculosis Vaccine Sales by Application (2020-2025) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of HumanTuberculosis Vaccine
Table 52. Key Market Challenges & Risks of HumanTuberculosis Vaccine
Table 53. Key IndustryTrends of HumanTuberculosis Vaccine
Table 54. HumanTuberculosis Vaccine Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. HumanTuberculosis Vaccine Distributors List
Table 57. HumanTuberculosis Vaccine Customer List
Table 58. Global HumanTuberculosis Vaccine SalesForecast by Region (2026-2031) & (K Units)
Table 59. Global HumanTuberculosis Vaccine RevenueForecast by Region (2026-2031) & ($ millions)
Table 60. Americas HumanTuberculosis Vaccine SalesForecast by Country (2026-2031) & (K Units)
Table 61. Americas HumanTuberculosis Vaccine Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 62. APAC HumanTuberculosis Vaccine SalesForecast by Region (2026-2031) & (K Units)
Table 63. APAC HumanTuberculosis Vaccine Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 64. Europe HumanTuberculosis Vaccine SalesForecast by Country (2026-2031) & (K Units)
Table 65. Europe HumanTuberculosis Vaccine RevenueForecast by Country (2026-2031) & ($ millions)
Table 66. Middle East & Africa HumanTuberculosis Vaccine SalesForecast by Country (2026-2031) & (K Units)
Table 67. Middle East & Africa HumanTuberculosis Vaccine RevenueForecast by Country (2026-2031) & ($ millions)
Table 68. Global HumanTuberculosis Vaccine SalesForecast byType (2026-2031) & (K Units)
Table 69. Global HumanTuberculosis Vaccine RevenueForecast byType (2026-2031) & ($ millions)
Table 70. Global HumanTuberculosis Vaccine SalesForecast by Application (2026-2031) & (K Units)
Table 71. Global HumanTuberculosis Vaccine RevenueForecast by Application (2026-2031) & ($ millions)
Table 72. GlaxoSmithKline Basic Information, HumanTuberculosis Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 73. GlaxoSmithKline HumanTuberculosis Vaccine Product Portfolios and Specifications
Table 74. GlaxoSmithKline HumanTuberculosis Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 75. GlaxoSmithKline Main Business
Table 76. GlaxoSmithKline Latest Developments
Table 77. Merck Basic Information, HumanTuberculosis Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 78. Merck HumanTuberculosis Vaccine Product Portfolios and Specifications
Table 79. Merck HumanTuberculosis Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 80. Merck Main Business
Table 81. Merck Latest Developments
Table 82. Serum Institute of India Basic Information, HumanTuberculosis Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 83. Serum Institute of India HumanTuberculosis Vaccine Product Portfolios and Specifications
Table 84. Serum Institute of India HumanTuberculosis Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 85. Serum Institute of India Main Business
Table 86. Serum Institute of India Latest Developments
Table 87. Valneva Basic Information, HumanTuberculosis Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 88. Valneva HumanTuberculosis Vaccine Product Portfolios and Specifications
Table 89. Valneva HumanTuberculosis Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Valneva Main Business
Table 91. Valneva Latest Developments
Table 92. ArchivelFarma Basic Information, HumanTuberculosis Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 93. ArchivelFarma HumanTuberculosis Vaccine Product Portfolios and Specifications
Table 94. ArchivelFarma HumanTuberculosis Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 95. ArchivelFarma Main Business
Table 96. ArchivelFarma Latest Developments
Table 97. BIOFABRI (Zendal) Basic Information, HumanTuberculosis Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 98. BIOFABRI (Zendal) HumanTuberculosis Vaccine Product Portfolios and Specifications
Table 99. BIOFABRI (Zendal) HumanTuberculosis Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 100. BIOFABRI (Zendal) Main Business
Table 101. BIOFABRI (Zendal) Latest Developments
Table 102. Japan BCG Laboratory Basic Information, HumanTuberculosis Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 103. Japan BCG Laboratory HumanTuberculosis Vaccine Product Portfolios and Specifications
Table 104. Japan BCG Laboratory HumanTuberculosis Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 105. Japan BCG Laboratory Main Business
Table 106. Japan BCG Laboratory Latest Developments
Table 107. GreenSignal Bio Pharma Basic Information, HumanTuberculosis Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 108. GreenSignal Bio Pharma HumanTuberculosis Vaccine Product Portfolios and Specifications
Table 109. GreenSignal Bio Pharma HumanTuberculosis Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 110. GreenSignal Bio Pharma Main Business
Table 111. GreenSignal Bio Pharma Latest Developments
Table 112. AJ Vaccines Basic Information, HumanTuberculosis Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 113. AJ Vaccines HumanTuberculosis Vaccine Product Portfolios and Specifications
Table 114. AJ Vaccines HumanTuberculosis Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 115. AJ Vaccines Main Business
Table 116. AJ Vaccines Latest Developments
Table 117.Taj Pharma India Basic Information, HumanTuberculosis Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 118.Taj Pharma India HumanTuberculosis Vaccine Product Portfolios and Specifications
Table 119.Taj Pharma India HumanTuberculosis Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 120.Taj Pharma India Main Business
Table 121.Taj Pharma India Latest Developments
Table 122. Biomed Lublin Basic Information, HumanTuberculosis Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 123. Biomed Lublin HumanTuberculosis Vaccine Product Portfolios and Specifications
Table 124. Biomed Lublin HumanTuberculosis Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 125. Biomed Lublin Main Business
Table 126. Biomed Lublin Latest Developments
LIST OFFIGURES
Figure 1. Picture of HumanTuberculosis Vaccine
Figure 2. HumanTuberculosis Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global HumanTuberculosis Vaccine Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global HumanTuberculosis Vaccine Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. HumanTuberculosis Vaccine Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. HumanTuberculosis Vaccine Sales Market Share by Country/Region (2024)
Figure 10. HumanTuberculosis Vaccine Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Intradermal
Figure 12. Product Picture of Percutaneous
Figure 13. Global HumanTuberculosis Vaccine Sales Market Share byType in 2025
Figure 14. Global HumanTuberculosis Vaccine Revenue Market Share byType (2020-2025)
Figure 15. HumanTuberculosis Vaccine Consumed in Pediatrics
Figure 16. Global HumanTuberculosis Vaccine Market: Pediatrics (2020-2025) & (K Units)
Figure 17. HumanTuberculosis Vaccine Consumed in Adults
Figure 18. Global HumanTuberculosis Vaccine Market: Adults (2020-2025) & (K Units)
Figure 19. Global HumanTuberculosis Vaccine Sale Market Share by Application (2024)
Figure 20. Global HumanTuberculosis Vaccine Revenue Market Share by Application in 2025
Figure 21. HumanTuberculosis Vaccine Sales by Company in 2025 (K Units)
Figure 22. Global HumanTuberculosis Vaccine Sales Market Share by Company in 2025
Figure 23. HumanTuberculosis Vaccine Revenue by Company in 2025 ($ millions)
Figure 24. Global HumanTuberculosis Vaccine Revenue Market Share by Company in 2025
Figure 25. Global HumanTuberculosis Vaccine Sales Market Share by Geographic Region (2020-2025)
Figure 26. Global HumanTuberculosis Vaccine Revenue Market Share by Geographic Region in 2025
Figure 27. Americas HumanTuberculosis Vaccine Sales 2020-2025 (K Units)
Figure 28. Americas HumanTuberculosis Vaccine Revenue 2020-2025 ($ millions)
Figure 29. APAC HumanTuberculosis Vaccine Sales 2020-2025 (K Units)
Figure 30. APAC HumanTuberculosis Vaccine Revenue 2020-2025 ($ millions)
Figure 31. Europe HumanTuberculosis Vaccine Sales 2020-2025 (K Units)
Figure 32. Europe HumanTuberculosis Vaccine Revenue 2020-2025 ($ millions)
Figure 33. Middle East & Africa HumanTuberculosis Vaccine Sales 2020-2025 (K Units)
Figure 34. Middle East & Africa HumanTuberculosis Vaccine Revenue 2020-2025 ($ millions)
Figure 35. Americas HumanTuberculosis Vaccine Sales Market Share by Country in 2025
Figure 36. Americas HumanTuberculosis Vaccine Revenue Market Share by Country (2020-2025)
Figure 37. Americas HumanTuberculosis Vaccine Sales Market Share byType (2020-2025)
Figure 38. Americas HumanTuberculosis Vaccine Sales Market Share by Application (2020-2025)
Figure 39. United States HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 40. Canada HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 41. Mexico HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 42. Brazil HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 43. APAC HumanTuberculosis Vaccine Sales Market Share by Region in 2025
Figure 44. APAC HumanTuberculosis Vaccine Revenue Market Share by Region (2020-2025)
Figure 45. APAC HumanTuberculosis Vaccine Sales Market Share byType (2020-2025)
Figure 46. APAC HumanTuberculosis Vaccine Sales Market Share by Application (2020-2025)
Figure 47. China HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 48. Japan HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 49. South Korea HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 50. Southeast Asia HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 51. India HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 52. Australia HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 53. ChinaTaiwan HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 54. Europe HumanTuberculosis Vaccine Sales Market Share by Country in 2025
Figure 55. Europe HumanTuberculosis Vaccine Revenue Market Share by Country (2020-2025)
Figure 56. Europe HumanTuberculosis Vaccine Sales Market Share byType (2020-2025)
Figure 57. Europe HumanTuberculosis Vaccine Sales Market Share by Application (2020-2025)
Figure 58. Germany HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 59.France HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 60. UK HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 61. Italy HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 62. Russia HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 63. Middle East & Africa HumanTuberculosis Vaccine Sales Market Share by Country (2020-2025)
Figure 64. Middle East & Africa HumanTuberculosis Vaccine Sales Market Share byType (2020-2025)
Figure 65. Middle East & Africa HumanTuberculosis Vaccine Sales Market Share by Application (2020-2025)
Figure 66. Egypt HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 67. South Africa HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 68. Israel HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 69.Turkey HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 70. GCC Countries HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 71. Manufacturing Cost Structure Analysis of HumanTuberculosis Vaccine in 2025
Figure 72. Manufacturing Process Analysis of HumanTuberculosis Vaccine
Figure 73. Industry Chain Structure of HumanTuberculosis Vaccine
Figure 74. Channels of Distribution
Figure 75. Global HumanTuberculosis Vaccine Sales MarketForecast by Region (2026-2031)
Figure 76. Global HumanTuberculosis Vaccine Revenue Market ShareForecast by Region (2026-2031)
Figure 77. Global HumanTuberculosis Vaccine Sales Market ShareForecast byType (2026-2031)
Figure 78. Global HumanTuberculosis Vaccine Revenue Market ShareForecast byType (2026-2031)
Figure 79. Global HumanTuberculosis Vaccine Sales Market ShareForecast by Application (2026-2031)
Figure 80. Global HumanTuberculosis Vaccine Revenue Market ShareForecast by Application (2026-2031)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Human Tuberculosis Vaccine Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Human Tuberculosis Vaccine by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Human Tuberculosis Vaccine by Country/Region, 2020, 2024 & 2031
2.2 Human Tuberculosis Vaccine Segment by Type
2.2.1 Intradermal
2.2.2 Percutaneous
2.3 Human Tuberculosis Vaccine Sales by Type
2.3.1 Global Human Tuberculosis Vaccine Sales Market Share by Type (2020-2025)
2.3.2 Global Human Tuberculosis Vaccine Revenue and Market Share by Type (2020-2025)
2.3.3 Global Human Tuberculosis Vaccine Sale Price by Type (2020-2025)
2.4 Human Tuberculosis Vaccine Segment by Application
2.4.1 Pediatrics
2.4.2 Adults
2.5 Human Tuberculosis Vaccine Sales by Application
2.5.1 Global Human Tuberculosis Vaccine Sale Market Share by Application (2020-2025)
2.5.2 Global Human Tuberculosis Vaccine Revenue and Market Share by Application (2020-2025)
2.5.3 Global Human Tuberculosis Vaccine Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Human Tuberculosis Vaccine Breakdown Data by Company
3.1.1 Global Human Tuberculosis Vaccine Annual Sales by Company (2020-2025)
3.1.2 Global Human Tuberculosis Vaccine Sales Market Share by Company (2020-2025)
3.2 Global Human Tuberculosis Vaccine Annual Revenue by Company (2020-2025)
3.2.1 Global Human Tuberculosis Vaccine Revenue by Company (2020-2025)
3.2.2 Global Human Tuberculosis Vaccine Revenue Market Share by Company (2020-2025)
3.3 Global Human Tuberculosis Vaccine Sale Price by Company
3.4 Key Manufacturers Human Tuberculosis Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Human Tuberculosis Vaccine Product Location Distribution
3.4.2 Players Human Tuberculosis Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR HUMAN TUBERCULOSIS VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Human Tuberculosis Vaccine Market Size by Geographic Region (2020-2025)
4.1.1 Global Human Tuberculosis Vaccine Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Human Tuberculosis Vaccine Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Human Tuberculosis Vaccine Market Size by Country/Region (2020-2025)
4.2.1 Global Human Tuberculosis Vaccine Annual Sales by Country/Region (2020-2025)
4.2.2 Global Human Tuberculosis Vaccine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Human Tuberculosis Vaccine Sales Growth
4.4 APAC Human Tuberculosis Vaccine Sales Growth
4.5 Europe Human Tuberculosis Vaccine Sales Growth
4.6 Middle East & Africa Human Tuberculosis Vaccine Sales Growth
5 AMERICAS
5.1 Americas Human Tuberculosis Vaccine Sales by Country
5.1.1 Americas Human Tuberculosis Vaccine Sales by Country (2020-2025)
5.1.2 Americas Human Tuberculosis Vaccine Revenue by Country (2020-2025)
5.2 Americas Human Tuberculosis Vaccine Sales by Type (2020-2025)
5.3 Americas Human Tuberculosis Vaccine Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Tuberculosis Vaccine Sales by Region
6.1.1 APAC Human Tuberculosis Vaccine Sales by Region (2020-2025)
6.1.2 APAC Human Tuberculosis Vaccine Revenue by Region (2020-2025)
6.2 APAC Human Tuberculosis Vaccine Sales by Type (2020-2025)
6.3 APAC Human Tuberculosis Vaccine Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Human Tuberculosis Vaccine by Country
7.1.1 Europe Human Tuberculosis Vaccine Sales by Country (2020-2025)
7.1.2 Europe Human Tuberculosis Vaccine Revenue by Country (2020-2025)
7.2 Europe Human Tuberculosis Vaccine Sales by Type (2020-2025)
7.3 Europe Human Tuberculosis Vaccine Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Human Tuberculosis Vaccine by Country
8.1.1 Middle East & Africa Human Tuberculosis Vaccine Sales by Country (2020-2025)
8.1.2 Middle East & Africa Human Tuberculosis Vaccine Revenue by Country (2020-2025)
8.2 Middle East & Africa Human Tuberculosis Vaccine Sales by Type (2020-2025)
8.3 Middle East & Africa Human Tuberculosis Vaccine Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Human Tuberculosis Vaccine
10.3 Manufacturing Process Analysis of Human Tuberculosis Vaccine
10.4 Industry Chain Structure of Human Tuberculosis Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Human Tuberculosis Vaccine Distributors
11.3 Human Tuberculosis Vaccine Customer
12 WORLD FORECAST REVIEW FOR HUMAN TUBERCULOSIS VACCINE BY GEOGRAPHIC REGION
12.1 Global Human Tuberculosis Vaccine Market Size Forecast by Region
12.1.1 Global Human Tuberculosis Vaccine Forecast by Region (2026-2031)
12.1.2 Global Human Tuberculosis Vaccine Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Human Tuberculosis Vaccine Forecast by Type (2026-2031)
12.7 Global Human Tuberculosis Vaccine Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 GlaxoSmithKline
13.1.1 GlaxoSmithKline Company Information
13.1.2 GlaxoSmithKline Human Tuberculosis Vaccine Product Portfolios and Specifications
13.1.3 GlaxoSmithKline Human Tuberculosis Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 GlaxoSmithKline Main Business Overview
13.1.5 GlaxoSmithKline Latest Developments
13.2 Merck
13.2.1 Merck Company Information
13.2.2 Merck Human Tuberculosis Vaccine Product Portfolios and Specifications
13.2.3 Merck Human Tuberculosis Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Merck Main Business Overview
13.2.5 Merck Latest Developments
13.3 Serum Institute of India
13.3.1 Serum Institute of India Company Information
13.3.2 Serum Institute of India Human Tuberculosis Vaccine Product Portfolios and Specifications
13.3.3 Serum Institute of India Human Tuberculosis Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Serum Institute of India Main Business Overview
13.3.5 Serum Institute of India Latest Developments
13.4 Valneva
13.4.1 Valneva Company Information
13.4.2 Valneva Human Tuberculosis Vaccine Product Portfolios and Specifications
13.4.3 Valneva Human Tuberculosis Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Valneva Main Business Overview
13.4.5 Valneva Latest Developments
13.5 Archivel Farma
13.5.1 Archivel Farma Company Information
13.5.2 Archivel Farma Human Tuberculosis Vaccine Product Portfolios and Specifications
13.5.3 Archivel Farma Human Tuberculosis Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Archivel Farma Main Business Overview
13.5.5 Archivel Farma Latest Developments
13.6 BIOFABRI (Zendal)
13.6.1 BIOFABRI (Zendal) Company Information
13.6.2 BIOFABRI (Zendal) Human Tuberculosis Vaccine Product Portfolios and Specifications
13.6.3 BIOFABRI (Zendal) Human Tuberculosis Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 BIOFABRI (Zendal) Main Business Overview
13.6.5 BIOFABRI (Zendal) Latest Developments
13.7 Japan BCG Laboratory
13.7.1 Japan BCG Laboratory Company Information
13.7.2 Japan BCG Laboratory Human Tuberculosis Vaccine Product Portfolios and Specifications
13.7.3 Japan BCG Laboratory Human Tuberculosis Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Japan BCG Laboratory Main Business Overview
13.7.5 Japan BCG Laboratory Latest Developments
13.8 GreenSignal Bio Pharma
13.8.1 GreenSignal Bio Pharma Company Information
13.8.2 GreenSignal Bio Pharma Human Tuberculosis Vaccine Product Portfolios and Specifications
13.8.3 GreenSignal Bio Pharma Human Tuberculosis Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 GreenSignal Bio Pharma Main Business Overview
13.8.5 GreenSignal Bio Pharma Latest Developments
13.9 AJ Vaccines
13.9.1 AJ Vaccines Company Information
13.9.2 AJ Vaccines Human Tuberculosis Vaccine Product Portfolios and Specifications
13.9.3 AJ Vaccines Human Tuberculosis Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 AJ Vaccines Main Business Overview
13.9.5 AJ Vaccines Latest Developments
13.10 Taj Pharma India
13.10.1 Taj Pharma India Company Information
13.10.2 Taj Pharma India Human Tuberculosis Vaccine Product Portfolios and Specifications
13.10.3 Taj Pharma India Human Tuberculosis Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Taj Pharma India Main Business Overview
13.10.5 Taj Pharma India Latest Developments
13.11 Biomed Lublin
13.11.1 Biomed Lublin Company Information
13.11.2 Biomed Lublin Human Tuberculosis Vaccine Product Portfolios and Specifications
13.11.3 Biomed Lublin Human Tuberculosis Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Biomed Lublin Main Business Overview
13.11.5 Biomed Lublin Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. HumanTuberculosis Vaccine Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. HumanTuberculosis Vaccine Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Intradermal
Table 4. Major Players of Percutaneous
Table 5. Global HumanTuberculosis Vaccine Sales byType (2020-2025) & (K Units)
Table 6. Global HumanTuberculosis Vaccine Sales Market Share byType (2020-2025)
Table 7. Global HumanTuberculosis Vaccine Revenue byType (2020-2025) & ($ million)
Table 8. Global HumanTuberculosis Vaccine Revenue Market Share byType (2020-2025)
Table 9. Global HumanTuberculosis Vaccine Sale Price byType (2020-2025) & (US$/Unit)
Table 10. Global HumanTuberculosis Vaccine Sale by Application (2020-2025) & (K Units)
Table 11. Global HumanTuberculosis Vaccine Sale Market Share by Application (2020-2025)
Table 12. Global HumanTuberculosis Vaccine Revenue by Application (2020-2025) & ($ million)
Table 13. Global HumanTuberculosis Vaccine Revenue Market Share by Application (2020-2025)
Table 14. Global HumanTuberculosis Vaccine Sale Price by Application (2020-2025) & (US$/Unit)
Table 15. Global HumanTuberculosis Vaccine Sales by Company (2020-2025) & (K Units)
Table 16. Global HumanTuberculosis Vaccine Sales Market Share by Company (2020-2025)
Table 17. Global HumanTuberculosis Vaccine Revenue by Company (2020-2025) & ($ millions)
Table 18. Global HumanTuberculosis Vaccine Revenue Market Share by Company (2020-2025)
Table 19. Global HumanTuberculosis Vaccine Sale Price by Company (2020-2025) & (US$/Unit)
Table 20. Key Manufacturers HumanTuberculosis Vaccine Producing Area Distribution and Sales Area
Table 21. Players HumanTuberculosis Vaccine Products Offered
Table 22. HumanTuberculosis Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global HumanTuberculosis Vaccine Sales by Geographic Region (2020-2025) & (K Units)
Table 26. Global HumanTuberculosis Vaccine Sales Market Share Geographic Region (2020-2025)
Table 27. Global HumanTuberculosis Vaccine Revenue by Geographic Region (2020-2025) & ($ millions)
Table 28. Global HumanTuberculosis Vaccine Revenue Market Share by Geographic Region (2020-2025)
Table 29. Global HumanTuberculosis Vaccine Sales by Country/Region (2020-2025) & (K Units)
Table 30. Global HumanTuberculosis Vaccine Sales Market Share by Country/Region (2020-2025)
Table 31. Global HumanTuberculosis Vaccine Revenue by Country/Region (2020-2025) & ($ millions)
Table 32. Global HumanTuberculosis Vaccine Revenue Market Share by Country/Region (2020-2025)
Table 33. Americas HumanTuberculosis Vaccine Sales by Country (2020-2025) & (K Units)
Table 34. Americas HumanTuberculosis Vaccine Sales Market Share by Country (2020-2025)
Table 35. Americas HumanTuberculosis Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 36. Americas HumanTuberculosis Vaccine Sales byType (2020-2025) & (K Units)
Table 37. Americas HumanTuberculosis Vaccine Sales by Application (2020-2025) & (K Units)
Table 38. APAC HumanTuberculosis Vaccine Sales by Region (2020-2025) & (K Units)
Table 39. APAC HumanTuberculosis Vaccine Sales Market Share by Region (2020-2025)
Table 40. APAC HumanTuberculosis Vaccine Revenue by Region (2020-2025) & ($ millions)
Table 41. APAC HumanTuberculosis Vaccine Sales byType (2020-2025) & (K Units)
Table 42. APAC HumanTuberculosis Vaccine Sales by Application (2020-2025) & (K Units)
Table 43. Europe HumanTuberculosis Vaccine Sales by Country (2020-2025) & (K Units)
Table 44. Europe HumanTuberculosis Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 45. Europe HumanTuberculosis Vaccine Sales byType (2020-2025) & (K Units)
Table 46. Europe HumanTuberculosis Vaccine Sales by Application (2020-2025) & (K Units)
Table 47. Middle East & Africa HumanTuberculosis Vaccine Sales by Country (2020-2025) & (K Units)
Table 48. Middle East & Africa HumanTuberculosis Vaccine Revenue Market Share by Country (2020-2025)
Table 49. Middle East & Africa HumanTuberculosis Vaccine Sales byType (2020-2025) & (K Units)
Table 50. Middle East & Africa HumanTuberculosis Vaccine Sales by Application (2020-2025) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of HumanTuberculosis Vaccine
Table 52. Key Market Challenges & Risks of HumanTuberculosis Vaccine
Table 53. Key IndustryTrends of HumanTuberculosis Vaccine
Table 54. HumanTuberculosis Vaccine Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. HumanTuberculosis Vaccine Distributors List
Table 57. HumanTuberculosis Vaccine Customer List
Table 58. Global HumanTuberculosis Vaccine SalesForecast by Region (2026-2031) & (K Units)
Table 59. Global HumanTuberculosis Vaccine RevenueForecast by Region (2026-2031) & ($ millions)
Table 60. Americas HumanTuberculosis Vaccine SalesForecast by Country (2026-2031) & (K Units)
Table 61. Americas HumanTuberculosis Vaccine Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 62. APAC HumanTuberculosis Vaccine SalesForecast by Region (2026-2031) & (K Units)
Table 63. APAC HumanTuberculosis Vaccine Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 64. Europe HumanTuberculosis Vaccine SalesForecast by Country (2026-2031) & (K Units)
Table 65. Europe HumanTuberculosis Vaccine RevenueForecast by Country (2026-2031) & ($ millions)
Table 66. Middle East & Africa HumanTuberculosis Vaccine SalesForecast by Country (2026-2031) & (K Units)
Table 67. Middle East & Africa HumanTuberculosis Vaccine RevenueForecast by Country (2026-2031) & ($ millions)
Table 68. Global HumanTuberculosis Vaccine SalesForecast byType (2026-2031) & (K Units)
Table 69. Global HumanTuberculosis Vaccine RevenueForecast byType (2026-2031) & ($ millions)
Table 70. Global HumanTuberculosis Vaccine SalesForecast by Application (2026-2031) & (K Units)
Table 71. Global HumanTuberculosis Vaccine RevenueForecast by Application (2026-2031) & ($ millions)
Table 72. GlaxoSmithKline Basic Information, HumanTuberculosis Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 73. GlaxoSmithKline HumanTuberculosis Vaccine Product Portfolios and Specifications
Table 74. GlaxoSmithKline HumanTuberculosis Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 75. GlaxoSmithKline Main Business
Table 76. GlaxoSmithKline Latest Developments
Table 77. Merck Basic Information, HumanTuberculosis Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 78. Merck HumanTuberculosis Vaccine Product Portfolios and Specifications
Table 79. Merck HumanTuberculosis Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 80. Merck Main Business
Table 81. Merck Latest Developments
Table 82. Serum Institute of India Basic Information, HumanTuberculosis Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 83. Serum Institute of India HumanTuberculosis Vaccine Product Portfolios and Specifications
Table 84. Serum Institute of India HumanTuberculosis Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 85. Serum Institute of India Main Business
Table 86. Serum Institute of India Latest Developments
Table 87. Valneva Basic Information, HumanTuberculosis Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 88. Valneva HumanTuberculosis Vaccine Product Portfolios and Specifications
Table 89. Valneva HumanTuberculosis Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Valneva Main Business
Table 91. Valneva Latest Developments
Table 92. ArchivelFarma Basic Information, HumanTuberculosis Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 93. ArchivelFarma HumanTuberculosis Vaccine Product Portfolios and Specifications
Table 94. ArchivelFarma HumanTuberculosis Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 95. ArchivelFarma Main Business
Table 96. ArchivelFarma Latest Developments
Table 97. BIOFABRI (Zendal) Basic Information, HumanTuberculosis Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 98. BIOFABRI (Zendal) HumanTuberculosis Vaccine Product Portfolios and Specifications
Table 99. BIOFABRI (Zendal) HumanTuberculosis Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 100. BIOFABRI (Zendal) Main Business
Table 101. BIOFABRI (Zendal) Latest Developments
Table 102. Japan BCG Laboratory Basic Information, HumanTuberculosis Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 103. Japan BCG Laboratory HumanTuberculosis Vaccine Product Portfolios and Specifications
Table 104. Japan BCG Laboratory HumanTuberculosis Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 105. Japan BCG Laboratory Main Business
Table 106. Japan BCG Laboratory Latest Developments
Table 107. GreenSignal Bio Pharma Basic Information, HumanTuberculosis Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 108. GreenSignal Bio Pharma HumanTuberculosis Vaccine Product Portfolios and Specifications
Table 109. GreenSignal Bio Pharma HumanTuberculosis Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 110. GreenSignal Bio Pharma Main Business
Table 111. GreenSignal Bio Pharma Latest Developments
Table 112. AJ Vaccines Basic Information, HumanTuberculosis Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 113. AJ Vaccines HumanTuberculosis Vaccine Product Portfolios and Specifications
Table 114. AJ Vaccines HumanTuberculosis Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 115. AJ Vaccines Main Business
Table 116. AJ Vaccines Latest Developments
Table 117.Taj Pharma India Basic Information, HumanTuberculosis Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 118.Taj Pharma India HumanTuberculosis Vaccine Product Portfolios and Specifications
Table 119.Taj Pharma India HumanTuberculosis Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 120.Taj Pharma India Main Business
Table 121.Taj Pharma India Latest Developments
Table 122. Biomed Lublin Basic Information, HumanTuberculosis Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 123. Biomed Lublin HumanTuberculosis Vaccine Product Portfolios and Specifications
Table 124. Biomed Lublin HumanTuberculosis Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 125. Biomed Lublin Main Business
Table 126. Biomed Lublin Latest Developments
LIST OFFIGURES
Figure 1. Picture of HumanTuberculosis Vaccine
Figure 2. HumanTuberculosis Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global HumanTuberculosis Vaccine Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global HumanTuberculosis Vaccine Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. HumanTuberculosis Vaccine Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. HumanTuberculosis Vaccine Sales Market Share by Country/Region (2024)
Figure 10. HumanTuberculosis Vaccine Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Intradermal
Figure 12. Product Picture of Percutaneous
Figure 13. Global HumanTuberculosis Vaccine Sales Market Share byType in 2025
Figure 14. Global HumanTuberculosis Vaccine Revenue Market Share byType (2020-2025)
Figure 15. HumanTuberculosis Vaccine Consumed in Pediatrics
Figure 16. Global HumanTuberculosis Vaccine Market: Pediatrics (2020-2025) & (K Units)
Figure 17. HumanTuberculosis Vaccine Consumed in Adults
Figure 18. Global HumanTuberculosis Vaccine Market: Adults (2020-2025) & (K Units)
Figure 19. Global HumanTuberculosis Vaccine Sale Market Share by Application (2024)
Figure 20. Global HumanTuberculosis Vaccine Revenue Market Share by Application in 2025
Figure 21. HumanTuberculosis Vaccine Sales by Company in 2025 (K Units)
Figure 22. Global HumanTuberculosis Vaccine Sales Market Share by Company in 2025
Figure 23. HumanTuberculosis Vaccine Revenue by Company in 2025 ($ millions)
Figure 24. Global HumanTuberculosis Vaccine Revenue Market Share by Company in 2025
Figure 25. Global HumanTuberculosis Vaccine Sales Market Share by Geographic Region (2020-2025)
Figure 26. Global HumanTuberculosis Vaccine Revenue Market Share by Geographic Region in 2025
Figure 27. Americas HumanTuberculosis Vaccine Sales 2020-2025 (K Units)
Figure 28. Americas HumanTuberculosis Vaccine Revenue 2020-2025 ($ millions)
Figure 29. APAC HumanTuberculosis Vaccine Sales 2020-2025 (K Units)
Figure 30. APAC HumanTuberculosis Vaccine Revenue 2020-2025 ($ millions)
Figure 31. Europe HumanTuberculosis Vaccine Sales 2020-2025 (K Units)
Figure 32. Europe HumanTuberculosis Vaccine Revenue 2020-2025 ($ millions)
Figure 33. Middle East & Africa HumanTuberculosis Vaccine Sales 2020-2025 (K Units)
Figure 34. Middle East & Africa HumanTuberculosis Vaccine Revenue 2020-2025 ($ millions)
Figure 35. Americas HumanTuberculosis Vaccine Sales Market Share by Country in 2025
Figure 36. Americas HumanTuberculosis Vaccine Revenue Market Share by Country (2020-2025)
Figure 37. Americas HumanTuberculosis Vaccine Sales Market Share byType (2020-2025)
Figure 38. Americas HumanTuberculosis Vaccine Sales Market Share by Application (2020-2025)
Figure 39. United States HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 40. Canada HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 41. Mexico HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 42. Brazil HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 43. APAC HumanTuberculosis Vaccine Sales Market Share by Region in 2025
Figure 44. APAC HumanTuberculosis Vaccine Revenue Market Share by Region (2020-2025)
Figure 45. APAC HumanTuberculosis Vaccine Sales Market Share byType (2020-2025)
Figure 46. APAC HumanTuberculosis Vaccine Sales Market Share by Application (2020-2025)
Figure 47. China HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 48. Japan HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 49. South Korea HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 50. Southeast Asia HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 51. India HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 52. Australia HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 53. ChinaTaiwan HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 54. Europe HumanTuberculosis Vaccine Sales Market Share by Country in 2025
Figure 55. Europe HumanTuberculosis Vaccine Revenue Market Share by Country (2020-2025)
Figure 56. Europe HumanTuberculosis Vaccine Sales Market Share byType (2020-2025)
Figure 57. Europe HumanTuberculosis Vaccine Sales Market Share by Application (2020-2025)
Figure 58. Germany HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 59.France HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 60. UK HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 61. Italy HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 62. Russia HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 63. Middle East & Africa HumanTuberculosis Vaccine Sales Market Share by Country (2020-2025)
Figure 64. Middle East & Africa HumanTuberculosis Vaccine Sales Market Share byType (2020-2025)
Figure 65. Middle East & Africa HumanTuberculosis Vaccine Sales Market Share by Application (2020-2025)
Figure 66. Egypt HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 67. South Africa HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 68. Israel HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 69.Turkey HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 70. GCC Countries HumanTuberculosis Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 71. Manufacturing Cost Structure Analysis of HumanTuberculosis Vaccine in 2025
Figure 72. Manufacturing Process Analysis of HumanTuberculosis Vaccine
Figure 73. Industry Chain Structure of HumanTuberculosis Vaccine
Figure 74. Channels of Distribution
Figure 75. Global HumanTuberculosis Vaccine Sales MarketForecast by Region (2026-2031)
Figure 76. Global HumanTuberculosis Vaccine Revenue Market ShareForecast by Region (2026-2031)
Figure 77. Global HumanTuberculosis Vaccine Sales Market ShareForecast byType (2026-2031)
Figure 78. Global HumanTuberculosis Vaccine Revenue Market ShareForecast byType (2026-2031)
Figure 79. Global HumanTuberculosis Vaccine Sales Market ShareForecast by Application (2026-2031)
Figure 80. Global HumanTuberculosis Vaccine Revenue Market ShareForecast by Application (2026-2031)
More Publications
Global Glioblastoma Treatment Drugs Market Growth 2025-2031
US$ 3,660.00
December 2025
99 pages
Global Ovarian Cancer Market Growth (Status and Outlook) 2024-2030
US$ 3,660.00
December 2024
93 pages
Global Artificial Shoulder Replacements Market Growth 2024-2030
US$ 3,660.00
August 2024
117 pages
Global Cholesterol Management Supplements Market Growth 2024-2030
US$ 3,660.00
December 2024
116 pages
Global Stone Management Disposables Market Growth 2024-2030
US$ 3,660.00
June 2024
76 pages
